These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
499 related articles for article (PubMed ID: 20215531)
1. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Gallagher DJ; Gaudet MM; Pal P; Kirchhoff T; Balistreri L; Vora K; Bhatia J; Stadler Z; Fine SW; Reuter V; Zelefsky M; Morris MJ; Scher HI; Klein RJ; Norton L; Eastham JA; Scardino PT; Robson ME; Offit K Clin Cancer Res; 2010 Apr; 16(7):2115-21. PubMed ID: 20215531 [TBL] [Abstract][Full Text] [Related]
2. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. Oh M; Alkhushaym N; Fallatah S; Althagafi A; Aljadeed R; Alsowaida Y; Jeter J; Martin JR; Babiker HM; McBride A; Abraham I Prostate; 2019 Jun; 79(8):880-895. PubMed ID: 30900310 [TBL] [Abstract][Full Text] [Related]
3. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer. Hamel N; Kotar K; Foulkes WD BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837 [TBL] [Abstract][Full Text] [Related]
4. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. Page EC; Bancroft EK; Brook MN; Assel M; Hassan Al Battat M; Thomas S; Taylor N; Chamberlain A; Pope J; Raghallaigh HN; Evans DG; Rothwell J; Maehle L; Grindedal EM; James P; Mascarenhas L; McKinley J; Side L; Thomas T; van Asperen C; Vasen H; Kiemeney LA; Ringelberg J; Jensen TD; Osther PJS; Helfand BT; Genova E; Oldenburg RA; Cybulski C; Wokolorczyk D; Ong KR; Huber C; Lam J; Taylor L; Salinas M; Feliubadaló L; Oosterwijk JC; van Zelst-Stams W; Cook J; Rosario DJ; Domchek S; Powers J; Buys S; O'Toole K; Ausems MGEM; Schmutzler RK; Rhiem K; Izatt L; Tripathi V; Teixeira MR; Cardoso M; Foulkes WD; Aprikian A; van Randeraad H; Davidson R; Longmuir M; Ruijs MWG; Helderman van den Enden ATJM; Adank M; Williams R; Andrews L; Murphy DG; Halliday D; Walker L; Liljegren A; Carlsson S; Azzabi A; Jobson I; Morton C; Shackleton K; Snape K; Hanson H; Harris M; Tischkowitz M; Taylor A; Kirk J; Susman R; Chen-Shtoyerman R; Spigelman A; Pachter N; Ahmed M; Ramon Y Cajal T; Zgajnar J; Brewer C; Gadea N; Brady AF; van Os T; Gallagher D; Johannsson O; Donaldson A; Barwell J; Nicolai N; Friedman E; Obeid E; Greenhalgh L; Murthy V; Copakova L; Saya S; McGrath J; Cooke P; Rønlund K; Richardson K; Henderson A; Teo SH; Arun B; Kast K; Dias A; Aaronson NK; Ardern-Jones A; Bangma CH; Castro E; Dearnaley D; Eccles DM; Tricker K; Eyfjord J; Falconer A; Foster C; Gronberg H; Hamdy FC; Stefansdottir V; Khoo V; Lindeman GJ; Lubinski J; Axcrona K; Mikropoulos C; Mitra A; Moynihan C; Rennert G; Suri M; Wilson P; Dudderidge T; ; Offman J; Kote-Jarai Z; Vickers A; Lilja H; Eeles RA Eur Urol; 2019 Dec; 76(6):831-842. PubMed ID: 31537406 [TBL] [Abstract][Full Text] [Related]
5. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. Castro E; Goh C; Olmos D; Saunders E; Leongamornlert D; Tymrakiewicz M; Mahmud N; Dadaev T; Govindasami K; Guy M; Sawyer E; Wilkinson R; Ardern-Jones A; Ellis S; Frost D; Peock S; Evans DG; Tischkowitz M; Cole T; Davidson R; Eccles D; Brewer C; Douglas F; Porteous ME; Donaldson A; Dorkins H; Izatt L; Cook J; Hodgson S; Kennedy MJ; Side LE; Eason J; Murray A; Antoniou AC; Easton DF; Kote-Jarai Z; Eeles R J Clin Oncol; 2013 May; 31(14):1748-57. PubMed ID: 23569316 [TBL] [Abstract][Full Text] [Related]
6. Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations. Agalliu I; Gern R; Leanza S; Burk RD Clin Cancer Res; 2009 Feb; 15(3):1112-20. PubMed ID: 19188187 [TBL] [Abstract][Full Text] [Related]
7. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1. Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ; J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670 [TBL] [Abstract][Full Text] [Related]
9. Prostate cancer progression and survival in BRCA2 mutation carriers. Tryggvadóttir L; Vidarsdóttir L; Thorgeirsson T; Jonasson JG; Olafsdóttir EJ; Olafsdóttir GH; Rafnar T; Thorlacius S; Jonsson E; Eyfjord JE; Tulinius H J Natl Cancer Inst; 2007 Jun; 99(12):929-35. PubMed ID: 17565157 [TBL] [Abstract][Full Text] [Related]
10. Germline breast cancer susceptibility gene mutations and breast cancer outcomes. Wang YA; Jian JW; Hung CF; Peng HP; Yang CF; Cheng HS; Yang AS BMC Cancer; 2018 Mar; 18(1):315. PubMed ID: 29566657 [TBL] [Abstract][Full Text] [Related]
11. Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer. Carter HB; Helfand B; Mamawala M; Wu Y; Landis P; Yu H; Wiley K; Na R; Shi Z; Petkewicz J; Shah S; Fantus RJ; Novakovic K; Brendler CB; Zheng SL; Isaacs WB; Xu J Eur Urol; 2019 May; 75(5):743-749. PubMed ID: 30309687 [TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. Rennert G; Bisland-Naggan S; Barnett-Griness O; Bar-Joseph N; Zhang S; Rennert HS; Narod SA N Engl J Med; 2007 Jul; 357(2):115-23. PubMed ID: 17625123 [TBL] [Abstract][Full Text] [Related]
13. BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Kirchhoff T; Kauff ND; Mitra N; Nafa K; Huang H; Palmer C; Gulati T; Wadsworth E; Donat S; Robson ME; Ellis NA; Offit K Clin Cancer Res; 2004 May; 10(9):2918-21. PubMed ID: 15131025 [TBL] [Abstract][Full Text] [Related]
14. Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation. Vicus D; Finch A; Rosen B; Fan I; Bradley L; Cass I; Sun P; Karlan B; McLaughlin J; Narod SA; Gynecol Oncol; 2010 Aug; 118(2):155-9. PubMed ID: 20452659 [TBL] [Abstract][Full Text] [Related]
15. Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. Nyberg T; Frost D; Barrowdale D; Evans DG; Bancroft E; Adlard J; Ahmed M; Barwell J; Brady AF; Brewer C; Cook J; Davidson R; Donaldson A; Eason J; Gregory H; Henderson A; Izatt L; Kennedy MJ; Miller C; Morrison PJ; Murray A; Ong KR; Porteous M; Pottinger C; Rogers MT; Side L; Snape K; Walker L; Tischkowitz M; Eeles R; Easton DF; Antoniou AC Eur Urol; 2020 Jan; 77(1):24-35. PubMed ID: 31495749 [TBL] [Abstract][Full Text] [Related]
16. Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer. Gallagher DJ; Cronin AM; Milowsky MI; Morris MJ; Bhatia J; Scardino PT; Eastham JA; Offit K; Robson ME BJU Int; 2012 Mar; 109(5):713-9. PubMed ID: 21756279 [TBL] [Abstract][Full Text] [Related]
17. Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status. Shah PD; Patil S; Dickler MN; Offit K; Hudis CA; Robson ME Cancer; 2016 Apr; 122(8):1178-84. PubMed ID: 26859126 [TBL] [Abstract][Full Text] [Related]
18. Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. Castro E; Goh C; Leongamornlert D; Saunders E; Tymrakiewicz M; Dadaev T; Govindasami K; Guy M; Ellis S; Frost D; Bancroft E; Cole T; Tischkowitz M; Kennedy MJ; Eason J; Brewer C; Evans DG; Davidson R; Eccles D; Porteous ME; Douglas F; Adlard J; Donaldson A; Antoniou AC; Kote-Jarai Z; Easton DF; Olmos D; Eeles R Eur Urol; 2015 Aug; 68(2):186-93. PubMed ID: 25454609 [TBL] [Abstract][Full Text] [Related]
19. Increased risk of male cancer and identification of a potential prostate cancer cluster region in BRCA2. Roed Nielsen H; Petersen J; Therkildsen C; Skytte AB; Nilbert M Acta Oncol; 2016; 55(1):38-44. PubMed ID: 26360800 [TBL] [Abstract][Full Text] [Related]
20. Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation. Willems AJ; Dawson SJ; Samaratunga H; De Luca A; Antill YC; Hopper JL; Thorne HJ; Clin Cancer Res; 2008 May; 14(10):2953-61. PubMed ID: 18445692 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]